Literature DB >> 28820267

Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.

Adam G Schwaid1, Ivan Cornella-Taracido1.   

Abstract

Compound potency is a key metric that is often used to drive medicinal chemistry programs. Compound potency is also taken into account when identifying the mechanism of action of compounds whose pharmacological target is unknown, particularly when these compounds are identified in phenotypic screens. Often compound potency is determined from assays using recombinantly generated, purified protein. It is well understood in the medicinal chemistry community that potency measured with recombinant enzyme and potency measured in cell may not entirely coincide. Decreases in cellular vs recombinant potency are often anticipated or explainable. What is less often realized is that compound potency can increase in a cellular environment due to several factors including cellular metabolism of compounds, protein-protein interactions, post-translational modifications, and asymmetric intracellular localization of compound. Here we discuss these factors and highlight examples where increases in cellular compound potency were critical to the development of probes or drugs.

Mesh:

Substances:

Year:  2017        PMID: 28820267     DOI: 10.1021/acs.jmedchem.7b00762

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  The human endogenous metabolome as a pharmacology baseline for drug discovery.

Authors:  Andreu Bofill; Xavier Jalencas; Tudor I Oprea; Jordi Mestres
Journal:  Drug Discov Today       Date:  2019-06-19       Impact factor: 7.851

2.  Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.

Authors:  Jing Tang; Ha T Do; Andrew D Huber; Mary C Casey; Karen A Kirby; Daniel J Wilson; Jayakanth Kankanala; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2019-02-02       Impact factor: 6.514

3.  6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H.

Authors:  Lei Wang; Jing Tang; Andrew D Huber; Mary C Casey; Karen A Kirby; Daniel J Wilson; Jayakanth Kankanala; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2018-07-17       Impact factor: 6.514

4.  Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.

Authors:  Upul K Bandarage; Alex M Aronov; Jingrong Cao; Jon H Come; Kevin M Cottrell; Robert J Davies; Simon Giroux; Marc Jacobs; Sudipta Mahajan; David Messersmith; Cameron S Moody; Rebecca Swett; Jinwang Xu
Journal:  ACS Med Chem Lett       Date:  2020-12-18       Impact factor: 4.345

5.  In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma.

Authors:  Hui Zhou; Meng Lei; Wang Wang; Mengjie Guo; Jia Wang; Haoyang Zhang; Li Qiao; Huayun Feng; Zhaogang Liu; Lijuan Chen; Jianhao Hou; Xueyuan Wang; Chenxi Gu; Bo Zhao; Evgeny Izumchenko; Ye Yang; Yongqiang Zhu
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.